BioSpace News Archive

Kamada Ltd., a plasma-derived biopharmaceutical company, announced that, following recent discussions with Takeda, it expects to receive approximately $25 million in revenues from the supply of GLASSIA® to Takeda in 2021.

Data Supported Accelerated Approvals of TAZVERIK for the Treatment of Both Epithelioid Sarcoma and Relapsed/Refractory Follicular Lymphoma

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the 2020 BIO Investor Forum Digital, being held virtually October 13-15, 2020.

IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers, announced that Alan S. Roemer, MBA, MPH has been appointed Chairman of the Company’s Board of Directors.

Todos Medical Ltd. announced that it has entered into an exclusive supply agreement with U.S. national mobile CLIA laboratory company Integrated Health LLC operating MOTOPARA Foundation’s mobile biosafety level 3-built laboratories developed to address the global COVID-19 pandemic.

Butterfly innovates with the most advanced Ultrasound-on-Chip™ technology, improving patient outcomes and efficiencies across global healthcare systems.

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that results from a large retrospective observational study of coronary orbital atherectomy will be released at TCT Connect 2020.

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract reporting preliminary data from KOMET-001, an ongoing clinical trial of the Company’s oral, potent and selective menin inhibitor, KO-539

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that abstracts submitted for two of its drug candidates have been selected for presentation at the Molecular Targets and Cancer Therapeutics virtual symposium hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and th

Pulse Biosciences, Inc. (Nasdaq: PLSE) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that clinical results from studies spanning the Company’s dermatologic application portfolio will be presented at the American Society for Dermatologic Surgery (ASDS) virtual annual meeting on October 9-11, 2020.